Search
Cintredekin besudotox
go.drugbank.com/drugs/DB05305InvestigationalCintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual
Casdatifan
go.drugbank.com/drugs/DB21701InvestigationalCasdatifan has a monoisotopic molecular weight of 439.09 Da. … Casdatifan is under investigation in clinical trial NCT07000149 (A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC)
Ceftiofur
go.drugbank.com/drugs/DB11485ExperimentalVet approvedIt is marketed by pharmaceutical company Zoetis as Excenel, and is the active ingredient in that company's Specramast LC (lactating cow formula) product. … The metabolite desfurolyceftiofur also has antibiotic activity, consequently the two compounds are measured together to monitor for antibiotic activity in the milk.
SNS-314
go.drugbank.com/drugs/DB06134InvestigationalSNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication an...
EPC2407
go.drugbank.com/drugs/DB05189InvestigationalEPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. It is intended for the treatment of advanced cancer patients with solid tumors that...
Surotomycin
go.drugbank.com/drugs/DB12076InvestigationalSurotomycin has a fourfold greater in vitro potency than vancomycin against C. … Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection.
Pancrelipase amylase
go.drugbank.com/drugs/DB11065ApprovedInvestigational[L2512] The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]
Beremagene geperpavec
go.drugbank.com/drugs/DB17831ApprovedInvestigationalDeveloped by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).
Eltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalEltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Tiotropium
go.drugbank.com/drugs/DB01409ApprovedInvestigational[A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]